# A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

> **NCT03888105** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 515 (actual)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma (B-NHL)

## Interventions

- **DRUG:** Odronextamab

## Key facts

- **NCT ID:** NCT03888105
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-13
- **Primary completion:** 2026-07-06
- **Final completion:** 2028-12-15
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888105, "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03888105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*